Arrow Capital Pty Ltd Invests $3.88 Million in Novo Nordisk A/S $NVO

Arrow Capital Pty Ltd purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 70,000 shares of the company’s stock, valued at approximately $3,884,000. Novo Nordisk A/S comprises 0.1% of Arrow Capital Pty Ltd’s portfolio, making the stock its 21st largest holding.

A number of other large investors also recently added to or reduced their stakes in NVO. True Wealth Design LLC boosted its position in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S in the third quarter valued at about $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S during the third quarter worth about $30,000. Allianz SE boosted its holdings in Novo Nordisk A/S by 70.0% during the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after buying an additional 238 shares during the last quarter. Finally, Financial Life Planners acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $33,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. HSBC reiterated a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $49.93.

Novo Nordisk A/S Trading Down 0.1%

NYSE NVO opened at $37.99 on Friday. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $82.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The stock’s 50 day moving average price is $50.14 and its two-hundred day moving average price is $51.77. The stock has a market capitalization of $169.61 billion, a price-to-earnings ratio of 10.95 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is currently 52.74%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.